Sep 24, 2021 This Week in Cardiology Podcast

Dual antiplatelet therapy after PCI, statin side effects, nightshift work and AF, and a cautionary note regarding therapeutic enthusiasm in HF care are the topics John Mandrola, MD, discusses in this week’s podcast. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I - COVID - Alaska Sets Record for Daily COVID Cases https://www.medscape.com/viewarticle/958999 II - MASTER DAPT - MASTER DAPT: 1 Month DAPT Enough After High-Bleeding-Risk PCI https://www.medscape.com/viewarticle/957463 - Antiplatelets and Anticoagulation Post-PCI: More on MASTER DAPT https://www.medscape.com/viewarticle/958002 - Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk https://www.nejm.org/doi/full/10.1056/NEJMoa2108749 - Abbreviated Antiplatelet Therapy in Patients at High Bleeding Risk With or Without Oral Anticoagulant Therapy After Coronary Stenting: An Open-Label, Randomized, Controlled Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.056680 III - Statins and Side Effects - Most Muscle Pain on Statins Not a Drug Effect: SAMSON in Print https://www.medscape.com/viewarticle/958877 - Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment https://doi.org/10.1016/j.jacc.2021.07.022 IV - Nightshift Work and AF - Regular Nightshift Work Linked to Atrial Fibrillation, CHD https://www.medscape.com/viewarticle/959346?src= - Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease https://doi.org/10.1093/eurheartj/ehab505 V - Enthusiasm for HF Therapy - Empagliflozin's HFpEF Efficacy Catalyzes Redefinition of HF https://www.medscape.com/viewarticle/959249 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD https://www.medscape.com/author/bob-harrington Questions or feedback, please contact [email protected]